Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
AYTU similar filings
- 23 Mar 22 Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for About Cotempla XR-ODT
- 3 Mar 22 Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
- 2 Mar 22 Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
- 14 Feb 22 Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
- 31 Jan 22 Aytu BioPharma Completes $15 Million Debt Refinancing
- 4 Jan 22 Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
- 13 Dec 21 Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
Filing view
External links